Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.50 |
| ▸ | DRD3 | P35462 | 14/20 | 0.50 |
| ▸ | DRD4 | P21917 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134428 | 1.00 | DRD2 (0.50) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6134562 | 0.90 | DRD2 (0.52) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6134559 | 0.90 | DRD2 (0.52) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6133898 | 0.85 | ADRB3 (0.49) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6133901 | 0.85 | ADRB3 (0.49) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8765981 | 0.79 | DRD2 (0.46) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8765828 | 0.79 | DRD2 (0.46) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL9541647 | 0.79 | DRD2 (0.46) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8765168 | 0.78 | DRD2 (0.46) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6134568 | 0.74 | DRD2 (0.41) | DRD2DRD3DRD4ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1483236-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076397-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | DRD2 130/4885DRD3 113/4885DRD4 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.